who

Myriad Genetics: Another Alzheimer's Compound Goes Down

why is bad news - discontinuation of drug in development - positive? save money that would have been spend to take the drug to next level and eventually onto the market?

or is it investors knew before that the potential drug would not make it to the market or be a flop - hence have already factored this as low price. instead a small profit of 750 mio for phase 3 trials for +2 billion company